Summary

In the Phase 3 Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen [VELOUR; NCT00561470] trial, aflibercept plus FOLFIRI improved overall survival (OS) compared with FOLFIRI plus placebo in patients with metastatic colorectal cancer. This subgroup analysis of the VELOUR trial evaluated the consistency of aflibercept's effect on OS and progression-free survival in a prespecified analysis of patients previously treated with bevacizumab.